CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing
出版年份 2019 全文链接
标题
CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing
作者
关键词
Adoptive T-cell immunotherapy, Retinoblastoma, CD171, GD2, Antigen loss, Sequential CAR-T cell therapy
出版物
BMC CANCER
Volume 19, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-09-09
DOI
10.1186/s12885-019-6131-1
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial
- (2018) Gregory L. Beatty et al. GASTROENTEROLOGY
- Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma
- (2018) Haneen Shalabi et al. HAEMATOLOGICA
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma
- (2018) Haneen Shalabi et al. HAEMATOLOGICA
- Checkpoint blockade reverses anergy in IL13Rα2 humanized scFv based CAR T cells to treat murine and canine gliomas.
- (2018) Yibo Yin et al. Molecular Therapy-Oncolytics
- CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
- (2017) Terry J Fry et al. NATURE MEDICINE
- Preclinical Assessment of CD171-Directed CAR T-cell Adoptive Therapy for Childhood Neuroblastoma: CE7 Epitope Target Safety and Product Manufacturing Feasibility
- (2016) Annette Künkele et al. CLINICAL CANCER RESEARCH
- Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy
- (2016) M. V. Maus et al. CLINICAL CANCER RESEARCH
- Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells
- (2016) Omkar U. Kawalekar et al. IMMUNITY
- Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
- (2016) Christine E. Brown et al. NEW ENGLAND JOURNAL OF MEDICINE
- Incidence of second cancers after radiotherapy and systemic chemotherapy in heritable retinoblastoma survivors: A report from the German reference center
- (2016) Petra Temming et al. PEDIATRIC BLOOD & CANCER
- Expression of neural cell adhesion molecule L1 (CD171) in neuroectodermal and other tumors: An immunohistochemical study of 5155 tumors and critical evaluation of CD171 prognostic value in gastrointestinal stromal tumors
- (2016) Shingo Inaguma et al. Oncotarget
- Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma
- (2016) Jaume Mora Expert Review of Clinical Pharmacology
- Disialoganglioside GD2 as a therapeutic target for human diseases
- (2015) Maya Suzuki et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
- (2015) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
- (2015) Adrienne H Long et al. NATURE MEDICINE
- The pharmacology of second-generation chimeric antigen receptors
- (2015) Sjoukje J. C. van der Stegen et al. NATURE REVIEWS DRUG DISCOVERY
- A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing
- (2015) Malvina Prapa et al. Oncotarget
- Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas-FasL-Dependent AICD
- (2015) A. Kunkele et al. Cancer Immunology Research
- Target Antigen Density Governs the Efficacy of Anti–CD20-CD28-CD3 ζ Chimeric Antigen Receptor–Modified Effector CD8+T Cells
- (2014) Keisuke Watanabe et al. JOURNAL OF IMMUNOLOGY
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity
- (2014) M. Hudecek et al. Cancer Immunology Research
- Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma
- (2013) Michael Roth et al. CANCER
- Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells
- (2013) M. Hudecek et al. CLINICAL CANCER RESEARCH
- The Basic Principles of Chimeric Antigen Receptor Design
- (2013) Michel Sadelain et al. Cancer Discovery
- Current Concepts for Diagnosis and Treatment of Retinoblastoma in Germany: Aiming for Safe Tumor Control and Vision Preservation
- (2012) P. Temming et al. KLINISCHE PADIATRIE
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc ‘spacer’ domain in the extracellular moiety of chimeric antigen receptors avoids ‘off-target’ activation and unintended initiation of an innate immune response
- (2010) A Hombach et al. GENE THERAPY
- Shedding of GD2 ganglioside in patients with retinoblastoma
- (2010) Jacques Portoukalian et al. INTERNATIONAL JOURNAL OF CANCER
- Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
- (2010) Alice L. Yu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo
- (2009) Michael C. Milone et al. MOLECULAR THERAPY
- Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains
- (2009) C. Carpenito et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More